HomeCardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO

San Diego, 29.05.2020

We are delighted to learn the most recent updates from Onvansertib (licensed from Nerviano Medical Sciences) :